722 related articles for article (PubMed ID: 18694829)
1. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW
Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829
[TBL] [Abstract][Full Text] [Related]
2. The thymus is required for the ability of FTY720 to prolong skin allograft survival across different histocompatibility MHC barriers.
del Rio ML; Pabst O; Ramirez P; Penuelas-Rivas G; Förster R; Rodriguez-Barbosa JI
Transpl Int; 2007 Oct; 20(10):895-903. PubMed ID: 17854447
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions.
Gollmann G; Neuwirt H; Tripp CH; Mueller H; Konwalinka G; Heufler C; Romani N; Tiefenthaler M
Int Immunol; 2008 Jul; 20(7):911-23. PubMed ID: 18495625
[TBL] [Abstract][Full Text] [Related]
4. FTY720 inhibits TH1-mediated allogeneic humoral immune response.
Peñuelas-Rivas G; Domínguez-Perles R; Brinkmann V; Del Rio ML; Muñoz-Luna A; Ramírez-Romero P; Parrilla-Paricio P; Rodríguez-Barbosa JI
Transplant Proc; 2005 Nov; 37(9):4124-6. PubMed ID: 16386642
[TBL] [Abstract][Full Text] [Related]
5. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo.
Yanagawa Y; Sugahara K; Kataoka H; Kawaguchi T; Masubuchi Y; Chiba K
J Immunol; 1998 Jun; 160(11):5493-9. PubMed ID: 9605152
[TBL] [Abstract][Full Text] [Related]
6. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus.
Chiba K; Matsuyuki H; Maeda Y; Sugahara K
Cell Mol Immunol; 2006 Feb; 3(1):11-9. PubMed ID: 16549044
[TBL] [Abstract][Full Text] [Related]
7. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors.
Chiba K
Pharmacol Ther; 2005 Dec; 108(3):308-19. PubMed ID: 15951022
[TBL] [Abstract][Full Text] [Related]
8. FTY720 in combination with cyclosporine--an analysis of skin allograft survival and renal function.
Silva FR; Silva LB; Cury PM; Burdmann EA; Bueno V
Int Immunopharmacol; 2006 Dec; 6(13-14):1911-8. PubMed ID: 17161344
[TBL] [Abstract][Full Text] [Related]
9. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
Morris MA; Gibb DR; Picard F; Brinkmann V; Straume M; Ley K
Eur J Immunol; 2005 Dec; 35(12):3570-80. PubMed ID: 16285007
[TBL] [Abstract][Full Text] [Related]
10. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo.
Wolf AM; Eller K; Zeiser R; Dürr C; Gerlach UV; Sixt M; Markut L; Gastl G; Rosenkranz AR; Wolf D
J Immunol; 2009 Sep; 183(6):3751-60. PubMed ID: 19692647
[TBL] [Abstract][Full Text] [Related]
11. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts.
Shimizu H; Takahashi M; Kaneko T; Murakami T; Hakamata Y; Kudou S; Kishi T; Fukuchi K; Iwanami S; Kuriyama K; Yasue T; Enosawa S; Matsumoto K; Takeyoshi I; Morishita Y; Kobayashi E
Circulation; 2005 Jan; 111(2):222-9. PubMed ID: 15642767
[TBL] [Abstract][Full Text] [Related]
12. A synthetic CD4-CDR3 peptide analog enhances skin allograft survival across a MHC class II barrier.
Koch U; Choksi S; Marcucci L; Korngold R
J Immunol; 1998 Jul; 161(1):421-9. PubMed ID: 9647252
[TBL] [Abstract][Full Text] [Related]
13. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing.
Chiba K; Yanagawa Y; Masubuchi Y; Kataoka H; Kawaguchi T; Ohtsuki M; Hoshino Y
J Immunol; 1998 May; 160(10):5037-44. PubMed ID: 9590253
[TBL] [Abstract][Full Text] [Related]
14. Rejection following donor or recipient preoperative treatment with FTY720 in rat small bowel transplantation.
Sakagawa T; Kiyochi H; Honda K; Kobayashi N
Transpl Immunol; 2004 Nov; 13(3):161-8. PubMed ID: 15381198
[TBL] [Abstract][Full Text] [Related]
15. The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology.
von Wenckstern H; Zimmermann K; Kleuser B
Arch Immunol Ther Exp (Warsz); 2006; 54(4):239-51. PubMed ID: 16830220
[TBL] [Abstract][Full Text] [Related]
16. FTY720 treatment prolongs skin graft survival in a completely incompatible strain combination.
Lima RS; Nogueira-Martins MF; Silva HT; Pestana JO; Bueno V
Transplant Proc; 2004 May; 36(4):1015-7. PubMed ID: 15194353
[TBL] [Abstract][Full Text] [Related]
17. Control of intestinal allograft rejection by FTY720 and costimulation blockade.
Yan S; Rodriguez-Barbosa JI; Pabst O; Beckmann JH; Brinkmann V; Förster R; Hoffmann MW
Transplant Proc; 2005; 37(1):114-5. PubMed ID: 15808565
[TBL] [Abstract][Full Text] [Related]
18. Effects of topical sphingosine-1-phosphate 1 receptor agonist on corneal allograft in mice.
Jia L; Liu Y; Wang L; Zhu J; Huang Y
Cornea; 2014 Apr; 33(4):398-404. PubMed ID: 24573171
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive and trafficking properties of donor splenic and bone marrow dendritic cells.
Emmanouilidis N; Guo Z; Dong Y; Newton-West M; Adams AB; Lee ED; Wang J; Pearson TC; Larsen CP; Newell KA
Transplantation; 2006 Feb; 81(3):455-62. PubMed ID: 16477234
[TBL] [Abstract][Full Text] [Related]
20. Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure.
Metzler B; Gfeller P; Wieczorek G; Li J; Nuesslein-Hildesheim B; Katopodis A; Mueller M; Brinkmann V
Int Immunol; 2008 May; 20(5):633-44. PubMed ID: 18343890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
